Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection

Angelo Iacobellis, Angelo Andriulli

Research output: Contribution to journalArticle

Abstract

Liver cirrhosis secondary to HCV infection is a chronic disorder that carries high morbidity and mortality. Approved antiviral treatment for this condition at present includes peginterferon in combination with ribavirin. Treatment is only recommended for a well-compensated liver cirrhosis, whereas antiviral therapy is commonly not implemented in cirrhotics with signs of liver decompensation, over the concern that the use of peginterferon and ribavirin might expose patients to severe treatment-related side effects. This review focuses on data available to support both efficacy and safety of antiviral therapy in both compensated and decompensated cirrhotic patients.

Original languageEnglish
Pages (from-to)1929-1938
Number of pages10
JournalExpert Opinion on Pharmacotherapy
Volume10
Issue number12
DOIs
Publication statusPublished - Aug 2009

Keywords

  • Antiviral therapy
  • Cirrhosis
  • HCV infection
  • Peginterferon
  • Ribavirin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Fingerprint Dive into the research topics of 'Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection'. Together they form a unique fingerprint.

  • Cite this